ReCOV

ReCOV
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular

ReCOV is a COVID-19 vaccine candidate developed by Jiangsu Rec-Biotechnology Co Ltd.[1][2][3][4]

References

  1. ↑ Clinical trial number NCT04818801 for "Safety, Reactogenicity and Immunogenicity Study of ReCOV" at ClinicalTrials.gov
  2. ↑ Clinical trial number NCT05084989 for "Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (ReCOV)" at ClinicalTrials.gov
  3. ↑ Allott A, McDonald L (24 June 2021). "New Covid-19 vaccine developed in China is being tested on Kiwis". Stuff. Retrieved 23 December 2021.
  4. ↑ "Coronavirus: China-made 'ReCov' vaccine may be better than Pfizer-BioNTech's, New Zealand doctor says; Sydney faces 'scariest period' of pandemic". South China Morning Post. 24 June 2021. Retrieved 23 December 2021.


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.